In the Senate of the United States, 
December 9, 2015. 
Resolved, That the bill from the House of Representa-
tives (H.R. 2820) entitled ‘‘An Act to reauthorize the Stem 
Cell Therapeutic and Research Act of 2005, and for other 
purposes.’’, do pass with the following 
AMENDMENT: 
Strike out all after the enacting clause and insert: 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Stem Cell Therapeutic 
and Research Reauthorization Act of 2015’’. 
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 
TRANSPLANTATION PROGRAM. 
(a) IN GENERAL.—Section 379(d)(2)(B) of the Public 
Health Service Act (42 U.S.C. 274k(d)(2)(B)) is amended— 
(1) by striking ‘‘remote collection’’ and inserting 
‘‘collection’’; and 
(2) by inserting ‘‘including remote collection,’’ 
after ‘‘cord blood units,’’.
† HR 2820 EAS 
(b) AUTHORIZATION
OF APPROPRIATIONS.—Section 
379B of the Public Health Service Act (42 U.S.C. 274m) 
is amended— 
(1) by striking ‘‘$30,000,000 for each of fiscal 
years 2011 through 2014 and’’; and 
(2) by inserting ‘‘and $30,000,000 for each of fis-
cal years 2016 through 2020’’ before the period at the 
end. 
(c) SECRETARY REVIEW ON STATE OF SCIENCE.—The 
Secretary of Health and Human Services, in consultation 
with the Director of the National Institutes of Health, the 
Commissioner of the Food and Drug Administration, and 
the Administrator of the Health Resources and Services Ad-
ministration, including the Advisory Council on Blood 
Stem Cell Transplantation established under section 379(a) 
of the Public Health Service Act (42 U.S.C. 274k(a)), and 
other stakeholders, where appropriate given relevant exper-
tise, shall conduct a review of the state of the science of 
using adult stem cells and birthing tissues to develop new 
types of therapies for patients, for the purpose of consid-
ering the potential inclusion of such new types of therapies 
in the C.W. Bill Young Cell Transplantation Program (es-
tablished under such section 379) in addition to the con-
tinuation of ongoing activities. Not later than June 30, 
2019, the Secretary shall submit to the Committee on
† HR 2820 EAS 
Health, Education, Labor, and Pensions of the Senate and 
the Committee on Energy and Commerce of the House of 
Representatives recommendations on the appropriateness of 
such new types of therapies for inclusion in the C.W. Bill 
Young Cell Transplantation Program. 
SEC. 3. CORD BLOOD INVENTORY. 
Section 2 of the Stem Cell Therapeutic and Research 
Act of 2005 (42 U.S.C. 274k note) is amended— 
(1) in subsection (a), by striking ‘‘one-time’’; 
(2) by striking subsection (c); 
(3) by redesignating subsections (d) through (h) 
as subsections (c) through (g), respectively; 
(4) in subsection (d) (as so redesignated)— 
(A) in paragraph (1), by striking ‘‘para-
graphs (2) and (3)’’ and inserting ‘‘paragraphs 
(2), (3), and (4)’’; 
(B) in paragraph (2)(B), by striking ‘‘sub-
section (d)’’ and inserting ‘‘subsection (c)’’; and 
(C) by adding at the end the following: 
‘‘(4) CONSIDERATION
OF
BEST
SCIENCE.—The 
Secretary shall take into consideration the best sci-
entific information available in order to maximize the 
number of cord blood units available for transplant 
when entering into contracts under this section, or
† HR 2820 EAS 
when extending a period of funding under such a con-
tract under paragraph (2). 
‘‘(5) CONSIDERATION OF BANKED UNITS OF CORD 
BLOOD.—In extending contracts pursuant to para-
graph (3), and determining new allocation amounts 
for the next contract period or contract extension for 
such cord blood bank, the Secretary shall take into ac-
count the number of cord blood units banked in the 
National Cord Blood Inventory by a cord blood bank 
during the previous contract period, in addition to 
consideration of the ability of such cord blood bank to 
increase the collection and maintenance of additional, 
genetically diverse cord blood units.’’; 
(5) in subsection (f) (as so redesignated)— 
(A) by striking paragraph (4); and 
(B) by redesignating paragraphs (5) and 
(6) as paragraphs (4) and (5), respectively; and 
(6) in subsection (g) (as so redesignated)— 
(A) in paragraph (1)— 
(i) by striking ‘‘$23,000,000 for each of 
fiscal years 2011 through 2014 and’’; and 
(ii) by inserting ‘‘and $23,000,000 for 
each of fiscal years 2016 through 2020’’ be-
fore the period at the end; and 
(B) by striking paragraph (2).
† HR 2820 EAS 
SEC. 4. DETERMINATION ON THE DEFINITION OF HUMAN 
ORGAN. 
Not later than one year after the date of enactment 
of this Act, the Secretary of Health and Human Services 
shall issue determinations with respect to the inclusion of 
peripheral blood stem cells and umbilical cord blood in the 
definition of human organ. 
Attest: 
Secretary.